American International Group Inc. raised its stake in AnaptysBio Inc (NASDAQ:ANAB) by 50.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,025 shares of the biotechnology company’s stock after buying an additional 4,053 shares during the period. American International Group Inc.’s holdings in AnaptysBio were worth $1,211,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ANAB. Evercore Wealth Management LLC purchased a new position in AnaptysBio in the third quarter valued at about $100,000. Legal & General Group Plc increased its holdings in AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 1,951 shares in the last quarter. New York State Common Retirement Fund purchased a new position in AnaptysBio in the second quarter valued at about $168,000. Nationwide Fund Advisors increased its holdings in AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,776 shares in the last quarter. Finally, Teachers Advisors LLC increased its holdings in AnaptysBio by 23.4% in the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 1,807 shares in the last quarter.
A number of research analysts have recently weighed in on ANAB shares. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a research note on Friday, November 10th. SunTrust Banks started coverage on shares of AnaptysBio in a research note on Wednesday, November 15th. They set a “buy” rating and a $115.00 price objective for the company. Royal Bank of Canada raised their price objective on shares of AnaptysBio to $108.00 and gave the stock an “outperform” rating in a research note on Monday, December 18th. Robert W. Baird reissued a “buy” rating and set a $144.00 price objective (up from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. Finally, Credit Suisse Group set a $135.00 price objective on shares of AnaptysBio and gave the stock an “outperform” rating in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $129.67.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.12. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $0.89 million. AnaptysBio’s revenue for the quarter was up 9.1% on a year-over-year basis. research analysts predict that AnaptysBio Inc will post -2.3 earnings per share for the current year.
WARNING: “AnaptysBio Inc (ANAB) Shares Bought by American International Group Inc.” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3252422/anaptysbio-inc-anab-shares-bought-by-american-international-group-inc.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.